라이트닝 바카라 사이트 Lab introduces antibody IV-to-SC conversion platform enabling high-capacity SC delivery through particle volume reduction

[by Ji, Yong Jun] "We have introduced 'IVL-BioFluidic,' a drug delivery system (DDS) platform capable of converting intravenous (IV) antibody therapeutics into subcutaneous (SC) formulations."

Kim Ju-hee, CEO of Inventage Lab, delivered these remarks during the ‘Pharmaceutical and Biotechnology Industry Innovation Forum,’ held on November 25 at the Oakwood Premier COEX Center in Seoul under the theme of ‘Global Competition and Response Strategies in the Era of Obesity Treatments.’

In her presentation titled ‘Next-Generation Formulation Innovation Driven by Microfluidic-Based Platforms,’ ​​Kim outlined the principles and development strategy of IVL-BioFluidic, an SC formulation conversion platform.

IVL-BioFluidic is a platform developed using the microfluidic-based DDS core technology introduced by 라이트닝 바카라 사이트 Lab in October. According to Kim, the platform enables the conversion of antibody drugs into SC formulations. In contrast to existing SC-converted antibody drugs, which typically require an additional component such as hyaluronidase, IVL-BioFluidic achieves high-dose SC delivery by adjusting particle volume.

"Conventional high-dose antibody drugs exhibit high viscosity, which makes it challenging to reduce the particle volume in the injection solution," Kim stated. "IVL-BioFluidic employs high-concentration technology to drastically reduce particle volume (to 2-3 mL), thereby enabling SC administration," she added.

Kim also pointed to global market trends that underscore the commercial potential of IVL-BioFluidic. Halozyme acquired Elektrofi, whose technology concept is similar to that of Inventage Lab, in a deal valued at around KRW 1.3 trillion (approximately USD 890 million) to convert IV formulations to SC formulations. Elektrofi's platform produces ‘microspheres’ from antibody solutions, disperses them within a non-aqueous carrier, and administers them as high-concentration subcutaneous injections.

Kim noted that this approach is comparable to the mechanism employed by Inventage Lab's IVL-BioFluidic platform. "In pharmacokinetic (PK) studies comparing SC formulations produced with IVL-BioFluidic to existing SC comparator formulations, we observed equivalent or higher blood drug concentrations (AUC)," she further commented.

Inventage Lab is developing long-acting therapeutics through its microfluidics-based DDS platform, IVL-DrugFluidic, which minimizes particle size variability to approximately 8% and achieves a stable PK profile. The central strategy is to enhance PK performance by maximizing particle quality. "The particles can remain stable for periods ranging from as short as three months to as long as one year," Kim explained.

라이트닝 바카라 사이트 Lab is currently conducting 35 pipeline projects in collaboration with Korean and international pharmaceutical companies utilizing this DDS technology. Following the signing of an additional joint research and development (R&D) agreement in 2024 with the multinational pharmaceutical company Boehringer Ingelheim, the company has continued to draw significant global attention.

"Had our partner company not held strong confidence in Inventage Lab's technological capabilities, securing an additional contract would have been unlikely," Kim stated. "We are currently pushing forward with development at a rapid pace," she added.